SCHEMBL8301823

SCHEMBL8301823

NC(=O)C1CC2CC2N1Cc1ccccc1

nearest known ligand 0.46

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
CYP3A4 P08684 5/20 0.46
KMT2A Q03164 2/20 0.46
KDM4E B2RXH2 1/20 0.46
ALDH1A1 P00352 1/20 0.46
KCNH2 Q12809 8/20 0.42
OPRK1 P41145 6/20 0.42
OPRM1 P35372 4/20 0.42
OPRD1 P41143 3/20 0.42
SIRT1 Q96EB6 1/20 0.42
CHRM2 P08172 1/20 0.41
CHRM4 P08173 1/20 0.41
CHRM5 P08912 1/20 0.41
PTGER4 P35408 2/20 0.41
DPP4 P27487 1/20 0.40
SPHK1 Q9NYA1 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3162914 1.00 CYP3A4 (0.46) CYP3A4KMT2AKDM4EALDH1A1KCNH2
SCHEMBL9356325 0.85 CHRM2 (0.47) KCNH2OPRK1OPRM1OPRD1SIRT1
SCHEMBL9356317 0.85 CHRM2 (0.47) KCNH2OPRK1OPRM1OPRD1SIRT1
SCHEMBL6685344 0.80 MAPT (0.44) ALDH1A1KCNH2OPRK1OPRM1OPRD1
SCHEMBL28842221 0.75 KCNH2 (0.47) KCNH2OPRK1OPRM1OPRD1SIRT1
SCHEMBL4399111 0.75 CYP3A4 (0.48) CYP3A4KMT2AKDM4EALDH1A1
SCHEMBL5954481 0.75 CYP3A4 (0.48) CYP3A4KMT2AKDM4EALDH1A1
SCHEMBL4616899 0.75 CYP3A4 (0.48) CYP3A4KMT2AKDM4EALDH1A1
SCHEMBL646159 0.75 CYP3A4 (0.48) CYP3A4KMT2AKDM4EALDH1A1OPRK1
SCHEMBL4399114 0.75 CYP3A4 (0.48) CYP3A4KMT2AKDM4EALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1658066-B9 ADAMANTYLGLYCINE- BASED INHIBITORS OF DIPEPTIDYL PEPTIDASE IV FOR THE TREATMENT OF DIABETES BRISTOL MYERS SQUIBB CO (US) 2010-02-24 EP disclosed
EP-1658066-B1 ADAMANTYLGLYCINE- BASED INHIBITORS OF DIPEPTIDYL PEPTIDASE IV FOR THE TREATMENT OF DIABETES BRISTOL MYERS SQUIBB CO (US) 2009-09-30 EP disclosed
EP-1997489-A1 Adamantylglycine derivatives as inhibitors of dipeptidyl peptidase IV for the treatment of diabetes BRISTOL-MYERS SQUIBB COMPANY (US) 2008-12-03 EP disclosed
WO-2005012249-A2 ADAMANTYGLYCINE- BASED INHIBITORS OF DIPEPTIDYL PEPTIDASE IV FOR THE TREATMENT OF DIABETES BRISTOL-MYERS SQUIBB COMPANY (US) 2005-02-10 WO disclosed